# Pharmacokinetics and Bioequivalence of Aterixen 100 mg Tablets and Aterixen 100 mg Film-coated Tablets in Healthy Volunteers

> **NCT06096571** · NA · UNKNOWN · sponsor: **Valenta Pharm JSC** · enrollment: 36 (estimated)

## Conditions studied

- Viral Infection COVID-19

## Interventions

- **DRUG:** Aterixen

## Key facts

- **NCT ID:** NCT06096571
- **Lead sponsor:** Valenta Pharm JSC
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-06-15
- **Primary completion:** 2024-12-15
- **Final completion:** 2024-12-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06096571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06096571, "Pharmacokinetics and Bioequivalence of Aterixen 100 mg Tablets and Aterixen 100 mg Film-coated Tablets in Healthy Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06096571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*